Cogent Biosciences, Inc.
Cogent Biosciences, Inc.
- Market cap
- $4.65B
Your view on COGT
Overview
What the company does, where it operates, and who runs it.
About Cogent Biosciences, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Andrew R. Robbins
- Headquarters
- 200 Cambridge Park Drive, Waltham, MA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Andrew R. Robbins
- Headquarters
- 200 Cambridge Park Drive, Waltham, MA, US
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases.
Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.
It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Stock Data
Price chart, volume, and trading data.
What moved it
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Cogent Biosciences, Inc.. Starting points for Cogent Biosciences, Inc.: EPS -$2.35, beta 0.34 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Cogent Biosciences, Inc.. Trailing twelve-month EPS for Cogent Biosciences, Inc. stands at -$2.35. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Buy
Targets, low to high
Analyst ratings
6 firms, last 12 months- Strong Buy0
- Buy5
- Hold1
- Sell0
- Strong Sell0
Earnings per share estimates
| Per share | This quarterDec 2020 | Next quarterMar 2025 | This yearYear to Dec 2026 | Next yearYear to Dec 2027 |
|---|---|---|---|---|
| Average estimate | −$0.51 | −$0.59 | −$2.33 | −$1.20 |
| Lowest estimate | −$0.51 | −$0.68 | −$2.45 | −$1.74 |
| Highest estimate | −$0.51 | −$0.49 | −$2.23 | −$0.42 |
| Number of analysts | 9 | 5 | 7 | 9 |
| A year ago | — | — | −$2.04 | — |
| Growth vs a year ago | — | — | −14.3% | — |
Revenue estimates
| Total | This quarterDec 2020 | Next quarterMar 2025 | This yearYear to Dec 2026 | Next yearYear to Dec 2027 |
|---|---|---|---|---|
| Average estimate | $50000.00 | $179933.00 | $5.44M | $287.93M |
| Lowest estimate | $50000.00 | $50761.00 | $2.15M | $141.39M |
| Highest estimate | $50000.00 | $267538.00 | $7.85M | $377.45M |
| Number of analysts | 5 | 5 | 8 | 9 |
| A year ago | — | — | $0.00 | — |
| Growth vs a year ago | — | — | — | — |
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Cogent Biosciences, Inc.. Cogent Biosciences, Inc. has reported as a listed company since 2018. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Industry | Mkt cap |
|---|---|---|---|---|---|
| AVBPArriVent BioPharma, Inc. Common Stock | Healthcare | Biotechnology | $544.1M | ||
| IDYAIDEAYA Biosciences, Inc. | Healthcare | Biotechnology | $2.5B | ||
| INCYIncyte Corporation | Healthcare | Biotechnology | $23.4B | ||
| KURAKura Oncology, Inc. | Healthcare | Biotechnology | $634.9M | ||
| MAZEMaze Therapeutics, Inc. | Healthcare | Biotechnology | $1.7B | ||
| NRIXNurix Therapeutics, Inc. | Healthcare | Biotechnology | $1.4B | ||
| RCUSArcus Biosciences, Inc. | Healthcare | Biotechnology | $2.2B | ||
| SNDXSyndax Pharmaceuticals, Inc. | Healthcare | Biotechnology | $785.0M | ||
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| FRX.TOFennec Pharmaceuticals Inc. | Healthcare | TSX | $681.0M | ||
| FTHFaeth Therapeutics, Inc. | Healthcare | NASDAQ | $203.1M | ||
| FTREFortrea Holdings Inc. | Healthcare | NASDAQ | $1.8B | ||
| FULCFulcrum Therapeutics, Inc. | Healthcare | NASDAQ | $281.8M | ||
| GALTGalectin Therapeutics Inc. | Healthcare | NASDAQ | $177.2M | ||
| GANXGain Therapeutics, Inc. | Healthcare | NASDAQ | $42.6M | ||
| GBIMGlobeImmune, Inc. | Healthcare | OTC | $575 | ||
| GBLXGB Sciences, Inc. | Healthcare | OTC | $122,121 | ||
| GDTCCytoMed Therapeutics Limited | Healthcare | NASDAQ | $8.9M | ||
| GENBGenerate Biomedicines, Inc. | Healthcare | NASDAQ | $1.2B | ||
| GENSFGenus plc | Healthcare | OTC | $2.5B | ||
| GERNGeron Corporation | Healthcare | NASDAQ | $560.9M | ||
| Ticker | Fund | Fund assets | % of the fund |
|---|---|---|---|
| IWMiShares Russell 2000 ETF | $76.6B in assets | 0.16% | |
| VTIVanguard Total Stock Market ETF | $689.2B in assets | 0.01% | |
| XBIState Street SPDR S&P Biotech ETF | $10.0B in assets | 1.15% | |
| VBVanguard Small-Cap ETF | $76.9B in assets | 0.06% | |
| LFSCF/M Emerald Life Sciences Innovation ETF | $125M in assets | 6.14% | |
| CANCTema Oncology ETF | $215M in assets | 4.38% | |
| VTWGVanguard Russell 2000 Growth ETF | $1.4B in assets | 0.34% | |
| IBBiShares Biotechnology ETF | $11.1B in assets | 0.31% | |
Largest holders first, then the funds most concentrated in COGT.
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold Cogent Biosciences, Inc., and how their positions are changing. At a $4.65B market value, institutional positions materially move Cogent Biosciences, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by Cogent Biosciences, Inc. executives and directors. Shares of Cogent Biosciences, Inc. have traded between $3.72 and $36.29 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
House Trading
U.S. Representative disclosures filed under the STOCK Act.
About this section
U.S. House of Representatives disclosures naming Cogent Biosciences, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Cogent Biosciences, Inc.. Coverage tracks Cogent Biosciences, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Cogent Biosciences, Inc.